Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned a consensus recommendation of “Hold” from the nine analysts that are presently covering the company, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $8.39.
Several equities research analysts recently commented on RVNC shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Mizuho dropped their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. HC Wainwright reissued a “neutral” rating and issued a $6.60 target price on shares of Revance Therapeutics in a research report on Friday, November 8th. StockNews.com initiated coverage on Revance Therapeutics in a research report on Tuesday, January 21st. They issued a “hold” rating for the company. Finally, Barclays reduced their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd.
View Our Latest Stock Report on Revance Therapeutics
Institutional Inflows and Outflows
Revance Therapeutics Stock Up 0.3 %
Shares of RVNC opened at $3.65 on Friday. The stock has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.86. The business has a 50-day simple moving average of $3.41 and a two-hundred day simple moving average of $4.60. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.56.
Revance Therapeutics (NASDAQ:RVNC – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. On average, equities research analysts expect that Revance Therapeutics will post -1.57 EPS for the current year.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
Further Reading
- Five stocks we like better than Revance Therapeutics
- Investing In Automotive Stocks
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- 3 Healthcare Dividend Stocks to Buy
- What Does the Future Hold for Eli Lilly?
- How Can Investors Benefit From After-Hours Trading
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.